Clinical Trials Clinical Research Therapeutics Regulatory Affairs Regulatory Approval Pharmaceutical Research AI in Healthcare Biotechnology Weight-loss Drugs Oncology FDA Approval FDA Regulations Biologics Therapeutic Research Stelara Loss of Exclusivity Mifepristone Ruling Alzheimer's Disease Intellectual Property Scientific Research Tyrosine Kinase Inhibitors Pharmaceuticals Combination Therapy GLP-1 Drugs Innovative Therapies Therapeutic Segments Preclinical Research Efficacy Studies Subcutaneous Administration Experimental Treatments Biosimilars Safety and Efficacy Research Studies Characterization Techniques Alzheimer's Phase 2 Trials Breakthrough Therapy Designation Phase 3 Trials Gene Therapy RNA-based Therapeutics Therapeutic Targets Drug Testing Research Applications Compounding Pharmacies Obesity Treatments Injectable Medications Disease Treatment
The filing sets a May 5 deadline for investors to seek a lead role in a case over alleged misstatements about a Phase 2b alopecia study.
